Quote:

---

For treatment of mild-moderate Covid 19, do you know how Leronlimab stacks up (or would stack up) vs another monoclonal antibody called Regkirona (regdanvimab)?

I just read an article that said regdanvimab has the best results against mild-moderate Covid of any existing treatment.

---

Regdanvimab binds to the spike protein stopping it from binding to the ACE2 receptor. In a phase 2/3 trial shows 50% less progression from mild/moderate to severe critical vs. standard of care. What the SOC is if any is unknown.

Definitely works, Earliest possible treatment would be better because a large upsurge in virus might overwhelm the amount of drug. Looking at trial criteria patients had to exhibit symptoms for less than 7 days, no limitation with leronlimab. Patients were excluded for any type of oxygen supplementation, with leronlimab exclusion was mechanical ventilation. Which looks like regdanvimab's trial veered more to the mild side.

Leronlimab's main mechanism of action is of course shutting down the inflammation caused by inflammatory factors. I also hypothesized that leronlimab could lower viral reproduction by disrupting the PI3K/AKT/mTORC1/4E-BP1 pathway dysregulating elF4E. Which was later affirmed in a cancer paper on leronlimab by Pestell. It also reverses the disruption of the immune system caused by the virus allowing it to kill off the virus more effectively.

How leronlimab compares? That's an unknown since the protocol was screwed up with some patients showing no symptomology and I don't think we ever received data on how many required hospitalization.